{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T02:14:13Z","timestamp":1648692853990},"reference-count":18,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2010]]},"DOI":"10.1536\/ihj.51.141","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T06:24:48Z","timestamp":1270621488000},"page":"141-145","source":"Crossref","is-referenced-by-count":3,"title":["Manageability of Acute Severe Heart Failure Complicated With Left Ventricular Thrombosis During Therapy for Breast Cancer"],"prefix":"10.1536","volume":"51","author":[{"given":"Sebastian","family":"Szmit","sequence":"first","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw"},{"name":"Department of Oncology, Military Institute of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Kurzyna","sequence":"additional","affiliation":[{"name":"Department of Chest Medicine, National Tuberculosis and Lung Diseases Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Gl\u00f3wczynska","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Kober","sequence":"additional","affiliation":[{"name":"Department of Chest Medicine, National Tuberculosis and Lung Diseases Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Czerniawska","sequence":"additional","affiliation":[{"name":"Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof J","family":"Filipiak","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezary","family":"Szczylik","sequence":"additional","affiliation":[{"name":"Department of Oncology, Military Institute of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"3","unstructured":"3. Slamon D, Eiermann W, Robert N, <i>et al<\/i>. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC&reg;T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC&reg;TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. http:\/\/www.abstracts2view.com\/sabcs06\/view.php?nu=SABCS06L_78."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61: 14-21. (Review)","DOI":"10.1159\/000055397"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1215"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Slamon DJ, Leyland-Jones B, Shak S, <i>et al<\/i>. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.","DOI":"10.1056\/NEJM200103153441101"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2.","DOI":"10.1200\/JCO.2005.05.827"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ewer MS, Vooletich MT, Durand JB, <i>et al<\/i>. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-6.","DOI":"10.1200\/JCO.2005.13.300"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Von Hoff DD, Layard MW, Basa P, <i>et al<\/i>. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60028-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Suter TM, Procter M, van Veldhuisen DJ, <i>et al<\/i>. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.","DOI":"10.1200\/JCO.2006.09.1611"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Perez EA, Suman VJ, Davidson NE, <i>et al<\/i>. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-8.","DOI":"10.1200\/JCO.2007.13.5467"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007; 116: 954-60. (Review)","DOI":"10.1161\/CIRCULATIONAHA.107.690487"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19: 1530-9.","DOI":"10.1093\/annonc\/mdn292"},{"key":"16","unstructured":"16. Jones AL, Verrill M, Barrett-Lee P, <i>et al<\/i>. Development and implementation of new UK National Cancer Research Institute (NCRI) guidelines for preventing and managing cardiac events with trastuzumab. Ann Oncol 2008; 19: viii85."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mackey JR, Clemons M, C&ocirc;t&eacute; MA, <i>et al<\/i>. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008; 15: 24-35.","DOI":"10.3747\/co.2008.199"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Perez EA, Romond EH, Suman VJ, <i>et al<\/i>. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with\/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25: 512.","DOI":"10.1200\/jco.2007.25.18_suppl.512"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/51\/2\/51_2_141\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T06:46:25Z","timestamp":1618814785000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/51\/2\/51_2_141\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.51.141","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}